Global Ozempic Market Size, Share & Forecast 2026-2031

The Global Ozempic Market was valued at USD 19 billion in 2025. The estimate is anchored to Novo Nordisk's reported Ozempic sales of DKK 127,089 million and normalized into USD using annual exchange-rate assumptions. Market value includes branded Ozempic product revenue generated through wholesale, retail-pharmacy, hospital, mail-order and authorized digital channels. It excludes Wegovy, Rybelsus, compounded semaglutide, illegal counterfeit products and distributor revenue already embedded in manufacturer sales to avoid double counting.

The market is forecast to grow at a 4.46% CAGR from 2025 to reach USD 25 billion by 2031. Treatment-equivalent volume is projected to expand faster, at approximately 9.24%, as diabetes prevalence rises and access improves. The lower value-growth rate reflects payer negotiations, international price mix, competition from tirzepatide and increasing lifecycle pressure. The forecast includes continued uptake for glycemic, cardiovascular and kidney-risk management but assumes no major unanticipated indication or abrupt global patent loss before 2031.

Profit pools are expected to shift from high-priced North American glycemic-control prescriptions toward broader cardiorenal use and international treatment volume. North America remains dominant, but its forecast growth is constrained by the Medicare maximum fair price taking effect in 2027. Asia Pacific and emerging regions offer faster volume expansion because large diabetes populations remain underpenetrated. Within clinical use, chronic kidney disease risk reduction should capture increasing strategic attention due to the substantial overlap between type 2 diabetes and CKD.

Net price compression is the most visible near-term constraint, followed by competition and lifecycle risk. Medicare's negotiated Ozempic price of USD 276.78 per pen becomes effective in January 2027 and represents approximately 71% savings from the referenced list price. Commercial payers can use public pricing benchmarks to seek additional rebates. At the same time, Mounjaro revenue reached USD 22.97 billion in 2025, showing that tirzepatide has become a major alternative within injectable type 2 diabetes treatment.

Asia Pacific offers the strongest regional expansion opportunity, with an estimated 8.9% CAGR through 2031. The region combines a large diabetes population with lower current Ozempic penetration than North America or Western Europe. Growth will depend on regulatory approvals, specialist capacity, reimbursement, affordability and cold-chain distribution. China, Japan, Australia and selected Southeast Asian markets provide distinct access models, requiring country-specific pricing and channel strategies rather than a uniform regional approach.

The expanding global type 2 diabetes population is the largest structural demand driver. The International Diabetes Federation estimated 589 million adults aged 20-79 were living with diabetes in 2024 and projects 853 million by 2050. This creates sustained demand for effective therapies, particularly products addressing multiple complications. Ozempic's cardiovascular and kidney-related indications strengthen its relevance because diabetes is a leading cause of kidney failure and commonly overlaps with cardiovascular disease.

Manufacturing capacity directly influences prescription fulfillment, market share and patient continuity. Novo Nordisk invested approximately USD 2 billion in United States manufacturing during 2025 and plans another USD 5.6 billion through 2028. The FDA declared the semaglutide injection shortage resolved in February 2025, but sustained demand requires continued investment in active ingredients, aseptic filling, device assembly and packaging. Capacity expansion also creates operational leverage, provided output remains aligned with product mix and regional reimbursement conditions.